Segantii Capital Management LTD Cerevel Therapeutics Holdings, Inc. Transaction History
Segantii Capital Management LTD
- $807 Million
- Q1 2024
A detailed history of Segantii Capital Management LTD transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Segantii Capital Management LTD holds 1,143,426 shares of CERE stock, worth $0. This represents 5.99% of its overall portfolio holdings.
Number of Shares
1,143,426
Previous 594,519
92.33%
Holding current value
$0
Previous $25.2 Million
91.74%
% of portfolio
5.99%
Previous 2.46%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
9Shares Held
5.01MCall Options Held
3.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
-
Kellner Capital, LLC New York, NY20.3KShares$01.55% of portfolio
-
Ifp Advisors, Inc764Shares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...